| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
GILD Overview
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Share Price & News
How has Gilead Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GILD is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: GILD's weekly volatility (2%) has been stable over the past year.
Market Performance
7 Day Return
1.8%
GILD
0.8%
US Biotechs
-1.8%
US Market
1 Year Return
13.1%
GILD
26.1%
US Biotechs
31.5%
US Market
Return vs Industry: GILD underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: GILD underperformed the US Market which returned 33% over the past year.
Shareholder returns
| GILD | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.8% | 0.8% | -1.8% |
| 30 Day | -1.0% | 2.3% | -0.9% |
| 90 Day | 7.6% | 5.5% | 0.8% |
| 1 Year | 18.1%13.1% | 27.7%26.1% | 33.5%31.5% |
| 3 Year | 7.6%-4.3% | 17.2%11.8% | 57.5%47.8% |
| 5 Year | 7.9%-9.5% | 45.2%34.1% | 119.1%95.3% |
Long-Term Price Volatility Vs. Market
How volatile is Gilead Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
Is Gilead Sciences (NASDAQ:GILD) Using Too Much Debt?1 week ago | Simply Wall St
Three Days Left Until Gilead Sciences, Inc. (NASDAQ:GILD) Trades Ex-Dividend1 month ago | Simply Wall St
Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 49%?Gilead Sciences Fundamentals Summary
| GILD fundamental statistics | |
|---|---|
| Market Cap | US$89.94b |
| Earnings (TTM) | US$5.16b |
| Revenue (TTM) | US$26.64b |
17.4x
P/E Ratio3.4x
P/S RatioIs GILD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GILD income statement (TTM) | |
|---|---|
| Revenue | US$26.64b |
| Cost of Revenue | US$4.41b |
| Gross Profit | US$22.23b |
| Expenses | US$17.07b |
| Earnings | US$5.16b |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.11 |
| Gross Margin | 83.45% |
| Net Profit Margin | 19.38% |
| Debt/Equity Ratio | 153.1% |
How did GILD perform over the long term?
See historical performance and comparisonDividends
4.0%
Current Dividend Yield68%
Payout RatioValuation
Is Gilead Sciences undervalued compared to its fair value and its price relative to the market?
48.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GILD ($71.73) is trading below our estimate of fair value ($138.14)
Significantly Below Fair Value: GILD is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GILD is good value based on its PE Ratio (17.4x) compared to the US Biotechs industry average (25.2x).
PE vs Market: GILD is good value based on its PE Ratio (17.4x) compared to the US market (17.5x).
Price to Earnings Growth Ratio
PEG Ratio: GILD is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: GILD is overvalued based on its PB Ratio (4.6x) compared to the US Biotechs industry average (3.1x).
Future Growth
How is Gilead Sciences forecast to perform in the next 1 to 3 years based on estimates from 24 analysts?
6.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GILD's forecast earnings growth (6.1% per year) is above the savings rate (2%).
Earnings vs Market: GILD's earnings (6.1% per year) are forecast to grow slower than the US market (14.9% per year).
High Growth Earnings: GILD's earnings are forecast to grow, but not significantly.
Revenue vs Market: GILD's revenue (0.9% per year) is forecast to grow slower than the US market (9.8% per year).
High Growth Revenue: GILD's revenue (0.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GILD's Return on Equity is forecast to be high in 3 years time (28.7%)
Past Performance
How has Gilead Sciences performed over the past 5 years?
-44.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GILD has a large one-off loss of $4.8B impacting its June 30 2021 financial results.
Growing Profit Margin: GILD became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GILD's earnings have declined by 44% per year over the past 5 years.
Accelerating Growth: GILD has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GILD has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: Whilst GILD's Return on Equity (26.06%) is high, this metric is skewed due to their high level of debt.
Financial Health
How is Gilead Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: GILD's short term assets ($13.9B) exceed its short term liabilities ($10.2B).
Long Term Liabilities: GILD's short term assets ($13.9B) do not cover its long term liabilities ($38.1B).
Debt to Equity History and Analysis
Debt Level: GILD's debt to equity ratio (153.1%) is considered high.
Reducing Debt: GILD's debt to equity ratio has increased from 137.5% to 153.1% over the past 5 years.
Debt Coverage: GILD's debt is well covered by operating cash flow (30.1%).
Interest Coverage: GILD's interest payments on its debt are well covered by EBIT (12.3x coverage).
Balance Sheet
Dividend
What is Gilead Sciences's current dividend yield, its reliability and sustainability?
3.96%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: GILD's dividend (3.96%) is higher than the bottom 25% of dividend payers in the US market (1.35%).
High Dividend: GILD's dividend (3.96%) is in the top 25% of dividend payers in the US market (3.65%)
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, GILD has been paying a dividend for less than 10 years.
Growing Dividend: GILD's dividend payments have increased, but the company has only paid a dividend for 6 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (67.6%), GILD's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: GILD's dividends in 3 years are forecast to be well covered by earnings (44% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.2yrs
Average management tenure
CEO
Dan O'Day (57 yo)
2.5yrs
Tenure
US$18,998,095
Compensation
Mr. Daniel P. O'Day, also known as Dan, serves as Member of Supervisory Board at Galapagos NV since October 22, 2019 . He served as Non-Independent Director at Galapagos NV since October 22, 2019 until Apr...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD19.00M) is above average for companies of similar size in the US market ($USD11.33M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: GILD's management team is considered experienced (2.2 years average tenure).
Board Members
Experienced Board: GILD's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Gilead Sciences, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Gilead Sciences, Inc.
- Ticker: GILD
- Exchange: NasdaqGS
- Founded: 1987
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$89.936b
- Shares outstanding: 1.25b
- Website: https://www.gilead.com
Number of Employees
Location
- Gilead Sciences, Inc.
- 333 Lakeside Drive
- Foster City
- California
- 94404
- United States
Listings
Biography
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. Th...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/09/22 00:09 |
| End of Day Share Price | 2021/09/21 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.